Seattle Genetics has completed the acquisition of Cascadian Therapeutics for $614m.

Based in Switzerland, Seattle Genetics is a biotechnology company, while Cascadian Therapeutics is a US-based biopharmaceutical company.

The target company is currently developing the oral tyrosine kinase inhibitor Tucatinib for the treatment of HER2 growth factor receptor overexpressed cancers.

Tucatinib is being investigated in a pivotal trial called HER2CLIMB. The drug has already demonstrated a favourable tolerability and efficacy profile in phase Ib trials.

The acquisition will strengthen Seattle Genetics’ late-stage cancer drug pipeline and establish it as a multi-product oncology company.

“Gryphon Investors has acquired Matrixx Initiatives from a division of H.I.G. Capital.”

Gryphon Investors has acquired Matrixx Initiatives from a division of H.I.G. Capital.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Based in the US, Gryphon Investors is a private equity firm, while Matrixx Initiatives, also based in the US, is an over-the-counter (OTC) healthcare company.

India-based private equity firm ChrysCapital has acquired a minority stake in Curatio Healthcare Pvt. Ltd for Rs1.3bn ($20m).

Based in India, the target company is a manufacturer of skincare products.

The managing director of Curatio, G.K. Ramani, and Fulcrum Venture India hold 67% of the share in the company, while the remaining share is held by Sequoia Capital.

Ramani has diluted his stake in the company and Fulcrum has made a partial exit.